238 related articles for article (PubMed ID: 24805896)
1. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA).
Konrad-Martin D; Reavis KM; McMillan G; Helt WJ; Dille M
J Rehabil Res Dev; 2014; 51(1):81-100. PubMed ID: 24805896
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
3. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
[TBL] [Abstract][Full Text] [Related]
4. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.
Dille MF; McMillan GP; Reavis KM; Jacobs P; Fausti SA; Konrad-Martin D
J Acoust Soc Am; 2010 Sep; 128(3):1163-74. PubMed ID: 20815453
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a cisplatin dose-ototoxicity model.
Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
[TBL] [Abstract][Full Text] [Related]
6. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
7. OtoID: new extended frequency, portable audiometer for ototoxicity monitoring.
Dille MF; Jacobs PG; Gordon SY; Helt WJ; McMillan GP
J Rehabil Res Dev; 2013; 50(7):997-1006. PubMed ID: 24301436
[TBL] [Abstract][Full Text] [Related]
8. Distortion-product otoacoustic emission test performance for ototoxicity monitoring.
Reavis KM; McMillan G; Austin D; Gallun F; Fausti SA; Gordon JS; Helt WJ; Konrad-Martin D
Ear Hear; 2011 Feb; 32(1):61-74. PubMed ID: 20625302
[TBL] [Abstract][Full Text] [Related]
9. Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients.
Eiamprapai P; Yamamoto N; Hiraumi H; Ogino-Nishimura E; Kitamura M; Hirano S; Ito J
Laryngoscope; 2012 Jun; 122(6):1392-6. PubMed ID: 22555987
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Controlled Trial Using Automated Technology for Improving Ototoxicity Monitoring in VA Oncology Patients.
Konrad-Martin D; O'Connell Bennett K; Garinis A; McMillan GP
Am J Audiol; 2021 Oct; 30(3S):870-886. PubMed ID: 34582263
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of distortion-product otoacoustic emissions-based ototoxicity monitoring using various primary frequency step-sizes.
McMillan GP; Konrad-Martin D; Dille MF
Int J Audiol; 2012 Sep; 51(9):689-96. PubMed ID: 22676700
[TBL] [Abstract][Full Text] [Related]
13. [Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia].
Lisowska G; Namysłowski G; Hajduk A; Polok A; Tomaszewska R; Misiołek M
Otolaryngol Pol; 2006; 60(3):415-20. PubMed ID: 16989457
[TBL] [Abstract][Full Text] [Related]
14. Hearing health and care: the need for improved hearing loss prevention and hearing conservation practices.
Fausti SA; Wilmington DJ; Helt PV; Helt WJ; Konrad-Martin D
J Rehabil Res Dev; 2005; 42(4 Suppl 2):45-62. PubMed ID: 16470464
[TBL] [Abstract][Full Text] [Related]
15. Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions.
Konrad-Martin D; Poling GL; Garinis AC; Ortiz CE; Hopper J; O'Connell Bennett K; Dille MF
Int J Audiol; 2018 Sep; 57(sup4):S3-S18. PubMed ID: 29157038
[TBL] [Abstract][Full Text] [Related]
16. Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C.
Casale M; Mazzarelli C; Vespasiani Gentilucci U; Potena M; Pappacena M; Faiella F; Galati G; Salvinelli F; Picardi A
Int J Immunopathol Pharmacol; 2012; 25(2):551-6. PubMed ID: 22697091
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.
Konrad-Martin D; James KE; Gordon JS; Reavis KM; Phillips DS; Bratt GW; Fausti SA
J Am Acad Audiol; 2010 May; 21(5):301-14; quiz 357. PubMed ID: 20569665
[TBL] [Abstract][Full Text] [Related]
18. Ototoxicity screening of patients treated with streptomycin using distortion product otoacoustic emissions.
Md Daud MK; Mohamadl H; Haron A; Rahman NA
B-ENT; 2014; 10(1):53-8. PubMed ID: 24765829
[TBL] [Abstract][Full Text] [Related]
19. Detection of cisplatin-induced ototoxicity with transient evoked otoacoustic emission test before pure tone audiometer.
Yilmaz S; Oktem F; Karaman E
Eur Arch Otorhinolaryngol; 2010 Jul; 267(7):1041-4. PubMed ID: 19946777
[TBL] [Abstract][Full Text] [Related]
20. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.
Al-Malky G; Dawson SJ; Sirimanna T; Bagkeris E; Suri R
J Cyst Fibros; 2015 Mar; 14(2):248-54. PubMed ID: 25127922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
